Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas

Next Previous
Trial Profile

A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NFX 179 (Primary)
  • Indications Neurofibroma; Neurofibromatosis 1
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Proof of concept
  • Sponsors NFlection Therapeutics

Most Recent Events

  • 11 Aug 2021 Status changed from recruiting to completed.
  • 26 May 2021 Primary endpoint of phospho-erk (p-ERK) levels of Target cNF Tumors in NFX-179 Gel group and Vehicle Gel group after 28 days of once-daily application has been met, according to results presented in a NFlection Therapeutics media release.
  • 26 May 2021 Results presented in a NFlection Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top